Literature DB >> 15049012

Immunologic monitoring of maintenance therapy for acute lymphoblastic leukaemia in children-preliminary report.

Wlodzimierz Luczynski1, Anna Stasiak-Barmuta, Maryna Krawczuk-Rybak.   

Abstract

BACKGROUND: In the study we evaluated immune reconstitution during maintenance therapy for acute lymphoblastic leukaemia (ALL) in relation to different treatment protocols and response of the immune system to the accompanying infections. PROCEDURE: The study group consisted of 40 children. The BFM protocol'90 was used in the standard risk group, while the New York protocol-in the high risk group. Assessment of the immune system was based on the analysis of peripheral blood mono-nuclear cells by flow cytometry and concentrations of immunoglobulins: G, M, A and IgE. Each patient was examined at 1-3 months' intervals.
RESULTS: Following cessation of intensive therapy, the successive months of maintenance treatment showed: (1) a considerable depletion of B lymphocytes, a durable decrease in IgM, IgA and gradually increasing IgG; (2) a correlation between the time passing from the cessation of intensive therapy and increased numbers and percentage of B cells, and the helper/suppressor cell ratio. In the group of children treated according to the high risk protocol, compared to the low-risk group patients, we found lower levels of the following parameters: IgG, % lymphocytes: B and T lymphocytes (including CD4/CD8 ratio and "naive"/"memory" ratio) and NK cells (% and count). During infection: (1) a significant increase was noted in the percentage of T cells with HLA co-expression and monocytes with ICAM-1 co-expression, (2) the percentage of CD3(+)CD45RO(+) "memory" T cells was found to increase.
CONCLUSIONS: Our findings indicate quantitative and qualitative changes of the immunity in children with ALL during maintenance therapy. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15049012     DOI: 10.1002/pbc.20018

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  2 in total

1.  Prevalence and Safety of Intravenous Immunoglobulin Administration During Maintenance Chemotherapy in Children with Acute Lymphoblastic Leukemia in First Complete Remission: A Health Maintenance Organization Perspective.

Authors:  Patrick Van Winkle; Raoul Burchette; Raymond Kim; Rukmani Raghunathan; Naveen Qureshi
Journal:  Perm J       Date:  2018

2.  Hypogammaglobulinemia in Adolescents and Young Adults with Acute Lymphoblastic Leukemia.

Authors:  Cassandra S Lange; April Rahrig; Sandra K Althouse; Robert P Nelson; Sandeep Batra
Journal:  J Adolesc Young Adult Oncol       Date:  2020-07-13       Impact factor: 1.757

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.